Reduced Dose Intravesical Bacillus Calmette-Guerin: Why It Might Not Matter

Ashish M. Kamat; Niyati Lobo; Seth P. Lerner; Roger Li; Justin T. Matulay; Joan Palou; J. Alfred Witjes; Morgan Roupret; Angela B. Smith; Sam S. Chang; Neal D. Shore; Gary D. Steinberg; Colin P. Dinney; Robert S. Svatek; Donald L. Lamm

doi:10.3233/BLC-211648

Reduced Dose Intravesical Bacillus Calmette-Guerin: Why It Might Not Matter

Ashish M. Kamat, Niyati Lobo, Seth P. Lerner, Roger Li, Justin T. Matulay, Joan Palou, J. Alfred Witjes, Morgan Roupret, Angela B. Smith, Sam S. Chang, Neal D. Shore, Gary D. Steinberg, Colin P. Dinney, Robert S. Svatek, Donald L. Lamm

Department of Urology

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

When it comes to the treatment of patients with non-muscle-invasive bladder cancer (NMIBC) with intravesical bacillus Calmette-Guerin (BCG), two questions must be considered: 1) what dose to give, and 2) for how long? The issue of optimal dose and duration has been the subject of several randomized trials and is especially pertinent in the context of a global BCG shortage. Despite this, there appears to be uncertainty as to whether BCG dose or duration may be compromised in the event of shortage. As such, we wish to summarize the available evidence as an aid to the practicing urologist.

Original language	English (US)
Pages (from-to)	113-117
Number of pages	5
Journal	Bladder Cancer
Volume	8
Issue number	2
DOIs	https://doi.org/10.3233/BLC-211648
State	Published - 2022

Keywords

Non-muscle-invasive bladder cancer
bacillus Calmette-Guerin
immunotherapy
reduced dose

ASJC Scopus subject areas

Oncology
Urology

Access to Document

10.3233/BLC-211648

Cite this

@article{e4561c07facc44af8330e75c745a33b1,

title = "Reduced Dose Intravesical Bacillus Calmette-Guerin: Why It Might Not Matter",

abstract = "When it comes to the treatment of patients with non-muscle-invasive bladder cancer (NMIBC) with intravesical bacillus Calmette-Guerin (BCG), two questions must be considered: 1) what dose to give, and 2) for how long? The issue of optimal dose and duration has been the subject of several randomized trials and is especially pertinent in the context of a global BCG shortage. Despite this, there appears to be uncertainty as to whether BCG dose or duration may be compromised in the event of shortage. As such, we wish to summarize the available evidence as an aid to the practicing urologist.",

keywords = "Non-muscle-invasive bladder cancer, bacillus Calmette-Guerin, immunotherapy, reduced dose",

author = "Kamat, {Ashish M.} and Niyati Lobo and Lerner, {Seth P.} and Roger Li and Matulay, {Justin T.} and Joan Palou and Witjes, {J. Alfred} and Morgan Roupret and Smith, {Angela B.} and Chang, {Sam S.} and Shore, {Neal D.} and Steinberg, {Gary D.} and Dinney, {Colin P.} and Svatek, {Robert S.} and Lamm, {Donald L.}",

year = "2022",

doi = "10.3233/BLC-211648",

language = "English (US)",

volume = "8",

pages = "113--117",

journal = "Bladder Cancer",

issn = "2352-3727",

publisher = "SAGE Publications Ltd",

number = "2",

}

TY - JOUR

T1 - Reduced Dose Intravesical Bacillus Calmette-Guerin

T2 - Why It Might Not Matter

AU - Kamat, Ashish M.

AU - Lobo, Niyati

AU - Lerner, Seth P.

AU - Li, Roger

AU - Matulay, Justin T.

AU - Palou, Joan

AU - Witjes, J. Alfred

AU - Roupret, Morgan

AU - Smith, Angela B.

AU - Chang, Sam S.

AU - Shore, Neal D.

AU - Steinberg, Gary D.

AU - Dinney, Colin P.

AU - Svatek, Robert S.

AU - Lamm, Donald L.

PY - 2022

Y1 - 2022

N2 - When it comes to the treatment of patients with non-muscle-invasive bladder cancer (NMIBC) with intravesical bacillus Calmette-Guerin (BCG), two questions must be considered: 1) what dose to give, and 2) for how long? The issue of optimal dose and duration has been the subject of several randomized trials and is especially pertinent in the context of a global BCG shortage. Despite this, there appears to be uncertainty as to whether BCG dose or duration may be compromised in the event of shortage. As such, we wish to summarize the available evidence as an aid to the practicing urologist.

AB - When it comes to the treatment of patients with non-muscle-invasive bladder cancer (NMIBC) with intravesical bacillus Calmette-Guerin (BCG), two questions must be considered: 1) what dose to give, and 2) for how long? The issue of optimal dose and duration has been the subject of several randomized trials and is especially pertinent in the context of a global BCG shortage. Despite this, there appears to be uncertainty as to whether BCG dose or duration may be compromised in the event of shortage. As such, we wish to summarize the available evidence as an aid to the practicing urologist.

KW - Non-muscle-invasive bladder cancer

KW - bacillus Calmette-Guerin

KW - immunotherapy

KW - reduced dose

UR - http://www.scopus.com/inward/record.url?scp=85131789813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85131789813&partnerID=8YFLogxK

U2 - 10.3233/BLC-211648

DO - 10.3233/BLC-211648

M3 - Article

AN - SCOPUS:85131789813

SN - 2352-3727

VL - 8

SP - 113

EP - 117

JO - Bladder Cancer

JF - Bladder Cancer

IS - 2

ER -

Reduced Dose Intravesical Bacillus Calmette-Guerin: Why It Might Not Matter

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this